Plasma Levels of E-cadherin and MMP-13 in Prostate Cancer Patients: Correlation with PSA, Testosterone and Pathological Parameters

Bonaldi, Carolina M; Azzalis, Ligia Ajaime; Junqueira, Virgínia; Oliveira, Claudia Giorgia Bronzatti de; Boas, Viviane Av; Gascón, Thaís Moura; Gehrke, Flávia S.; Kuniyoshi, Renata Kelly; Alves, Beatriz da Costa Aguiar; Fonseca, Fernando L. A.

doi:10.5301/tj.5000237

Cited by 10 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In colorectal patients, Velikova et al 33 determined that there was no statistically significant difference between sE-cadherin levels between controls and patients. However, Bonaldi et al 17 suggested that sE-cadherin was lower in patients with prostate cancer compared to controls. Several studies concluded that decreased expression of E-cadherin facilitated tumor invasion and metastasis in various tumors such as ovarian, endometrial and cervical cancers.…”

Section: Turan Et Al Vitronectin Se-cadherin and Tgf-β1 Levels In Ementioning

confidence: 99%

See 1 more Smart Citation

Assessment of Vitronectin, Soluble Epithelial-Cadherin and TGF-β1 as a Serum Biomarker with Predictive Value for Endometrial and Ovarian Cancers

Turan

Torun

Atalay

et al. 2017

tjps

View full text Add to dashboard Cite

ÖZAmaç: Vitronektin, çözünür epitelyal-cadherin (sE-cadherin) ve transforming büyüme faktörü-beta 1'i (TGF-β1) içeren ekstrasellüler matriks elemanları kanserin invazyonu ve metastazında anahtar rol oynamaktadır. Bu çalışmada endometriyal ve over kanserli hastalarda bu moleküllerin serum düzeylerinin klinik önemini belirlemek amaçlanmıştır. Gereç ve Yöntemler: Bu çalışmada, 28 endometriyum kanseri hastası, 40 over kanseri hastası ve 41 sağlıklı kontrol grubuna ait serum vitronektin (VN), sE-cadherin ve TGF-β1 düzeyleri ELISA yöntemiyle ticari kitler kullanılarak ölçülmüştür. Bulgular: Total hasta grubunda, sağlıklı kontrollere kıyasla VN, sE-cadherin ve TGF-β1 düzeylerinde anlamlı bir farklılık bulunmuştur (sırasıyla p<0,01; p<0,01 ve p<0,05). Serum VN ve sE-cadherin düzeyleri hem endometriyal hem de over kanseri hastalarında kontrol grubuna kıyasla önemli ölçüde düşük bulunmuştur (p<0,01). Buna karşın, TGF-β1 düzeyleri, kontrol grubuna kıyasla over kanserinde anlamlı derecede yükselmiştir (p<0,01), ancak sağlıklı kontroller ile endometriyal kanserli hastalar arasında anlamlı bir fark bulunamamıştır. Sonuç: Çalışmamız serum VN ve sE-cadherin düzeylerinin, endometriyal ve over kanserlerinde yeni tanı yöntemleri sağlamak için aday hedefler olabileceğini ortaya koymaktadır. Anahtar kelimeler: Vitronektin, sE-cadherin, TGF-β1, endometriyal kanser, over kanseri Objectives: Extracellular matrix components, including vitronectin (VN), soluble epithelial-cadherin (sE-cadherin) and transforming growth factorbeta 1 (TGF-β1), play a key role in the invasion and metastasis of cancer. The objective of the study was to determine the clinical significance of serum levels of these molecules in patients with endometrial and ovarian cancers. Materials and Methods: Serum levels of VN, sE-cadherin and TGF-β1 in patients with endometrial (n=28) and ovarian cancers (n=40) and healthy controls (n=41) were measured by ELISA using commercial kits. Results: A significant difference was found in VN, sE-cadherin and TGF-β1 levels between patients and healthy controls (p<0.01, p<0.01 and p<0.05, respectively). Serum VN and sE-cadherin levels were decreased significantly in both endometrial and ovarian cancer patients compared to controls (p<0.01, p<0.01, respectively). Conversely, TGF-β1 levels were increased significantly in patients with ovarian cancer as compared to controls (p<0.01). There was no significant difference between healthy controls and endometrial cancer patients. Conclusion: In conclusion, our study reveals that serum VN, sE-cadherin and TGF-β1 levels can be candidate targets for providing new diagnostic procedures in endometrial and ovarian cancers.

show abstract

Section: Turan Et Al Vitronectin Se-cadherin and Tgf-β1 Levels In Ementioning

confidence: 99%

“…15 But, there are conflicting results about soluble E-cadherin (sE-cadherin) levels in cancer. Some suggest that serum sE-cadherin levels were higher, 16 while others were revealed that sE-cadherin levels were significantly lower 17 in patients compared to controls.…”

Section: Introductionmentioning

confidence: 99%

Assessment of Vitronectin, Soluble Epithelial-Cadherin and TGF-β1 as a Serum Biomarker with Predictive Value for Endometrial and Ovarian Cancers

Turan

Torun

Atalay

et al. 2017

tjps

View full text Add to dashboard Cite

show abstract

“…The loss of this adhesion molecule is accompanied by increases in other mesenchymal markers such as N-cadherin, vimentin and fibronectin [51]. An increasing number of studies demonstrate that in many tumours including prostate, loss of E-cadherin increases tumour cell motility and invasiveness and is associated with poor prognosis in cancer patients [39,[52][53][54]. Similarly, examination of prostate cancer tissue samples using immunohistochemistry also revealed a reduction in the expression of cellular membrane E-cadherin that was concomitant with increasing Gleason score, clinical stage and a decline in survival [55].…”

Section: Emt and Prostate Cancer Progressionmentioning

confidence: 99%

“…In the clinical setting, plasma concentrations of E-cadherin are low in the later stage of prostate cancer patients and correlate with raised levels of PSA. In keeping with this, the use of plasma E-cadherin concentrations as a biomarker of the metastatic potential and to predict prognosis of prostate cancer has been proposed in clinical practice along with the use of PSA, particularly when aberrant modification of E-cadherin is likely to be involved in cancer invasion [53]. In addition to this, in vivo and in vitro studies have found that inhibition of N-cadherin using antibodies is able to delay the progression of prostate cancer to castration resistance and also to inhibit the invasion and metastasis of castrationresistant tumour growth suggesting the fundamental role of N-cadherin in promoting castration resistance and metastasis [56].…”

Section: Emt and Prostate Cancer Progressionmentioning

confidence: 99%

The Role of the IGF Axis in Epithelial-to-Mesenchymal Transition during the Progression of Prostate Cancer

Mansor¹,

Bahl²,

Holly³

et al. 2015

J. Anal. Oncol.

View full text Add to dashboard Cite

Prostate cancer is the second most common lethal cancer in men worldwide. Despite the fact that the prognosis for patients with localized disease is good, many patients succumb to metastatic disease with the development of resistance to hormone treatments. This is normally termed castration-resistant prostate cancer (CRPC). The development of metastatic, castration-resistant prostate cancer has been associated with epithelial-to-mesenchymal transition (EMT), a process where cancer cells acquire a more mesenchymal phenotype with enhanced migratory potential, invasiveness and elevated resistance to apoptosis. The main event in EMT is the repression of epithelial markers such as E-cadherin and upregulation of mesenchymal markers such as N-cadherin, vimentin and fibronectin. The insulin-like growth factor (IGF) signalling axis is essential for normal development and maintenance of tissues, including that of the prostate, and dysregulation of this pathway contributes to prostate cancer progression and malignant transformation. It is becoming increasingly clear that one of the ways in which the IGF axis impacts upon cancer progression is through promoting EMT. This review will explore the role of EMT in prostate cancer progression with a specific focus on the involvement of the IGF axis and its downstream signalling pathways in regulating EMT in prostate cancer.Keywords: Epithelial-to-mesenchymal transition, insulin-like growth factor family, prostate cancer progression, lifestyle factors. PROSTATE CANCERProstate cancer is the second most common lethal cancer diagnosed in men. According to The American Cancer Society, it is estimated that more than 220 000 new cases of prostate cancer will occur in the United States during 2015 accounting for about 26% of all cancers in men with a mortality rate of 9%: the second highest cause of cancer deaths in men after lung cancer [1].Age is the biggest risk factor for PCa with the incidence of prostate cancer being higher in older men particularly in men aged 65 and above [2]. The incidence of, and mortality from, prostate cancer varies hugely within different racial and ethnic groups. Much higher incidence and death rates are reported in black men compared to other races [3,4]: the reasons underlying these observations are still unclear but both genetic and/or environmental influences may be involved. A number of epidemiology studies have also reported that family history is a risk factor for PCa-with approximately 5-10% of cases being attributable to inherited genetic factors or PCa susceptibility genes [5,6] The prognosis for patients with localized disease is good, however the morbidity and mortality for prostate cancer patients who develop metastatic disease is high [7]. Androgen deprivation therapy (ADT) which involves surgical or chemical castration plays an important role in the treatment and management of prostate cancer and is also utilised as an adjuvant or neo-adjuvant treatment for high-risk disease [8]. The response to the treatments is however temporary a...

show abstract

“…The plasma concentration of MMP13 can have a diagnostic role in a prostatic carcinoma patient. (10,11) The expression of several MMPs and TIMPs in prostatic carcinoma like MMP 2, 7, 9, 13 and 4 and TIMP 1 and 2 have recently been reported (7,12,13) and shows that overexpression of MMPs induces tumour growth. (14,15) The proteins encoded by TIMP gene family are natural inhibitors of matrix metalloproteinases.…”

mentioning

confidence: 99%

Can Levels of Urinary Matrix Metalloproteinases (Mmps) Act as an Alternative to Gleason’s Scoring in Prostatic Malignancies

Banerjee¹,

K²,

K³

et al. 2017

jemds

View full text Add to dashboard Cite

show abstract

Plasma Levels of E-cadherin and MMP-13 in Prostate Cancer Patients: Correlation with PSA, Testosterone and Pathological Parameters

Abstract: The results suggest that these parameters could be used both in the diagnosis and prognosis of prostate cancer.

Cited by 10 publications

References 12 publications

Assessment of Vitronectin, Soluble Epithelial-Cadherin and TGF-β1 as a Serum Biomarker with Predictive Value for Endometrial and Ovarian Cancers

Assessment of Vitronectin, Soluble Epithelial-Cadherin and TGF-β1 as a Serum Biomarker with Predictive Value for Endometrial and Ovarian Cancers

The Role of the IGF Axis in Epithelial-to-Mesenchymal Transition during the Progression of Prostate Cancer

Can Levels of Urinary Matrix Metalloproteinases (Mmps) Act as an Alternative to Gleason’s Scoring in Prostatic Malignancies

Contact Info

Product

Resources

About